R&D On the power of T-cells, with Cedrik Britten Dr Cedrik Britten, chief medical officer at Immatics, discusses novel PRAME-directed T-cell immunotherapies.
R&D Biopharma’s future in Ireland: Stability, regulation & talen... As increasing global competition from incentives is felt globally, Ireland needs to become even more agile.
R&D Sponsored 12 Questions with Matthew Goodman LUCENT Biopharma's Medical Director Matthew Goodman, a doctor by training, specialises in late-phase Clinical Development and Medical Affairs.
R&D When biology becomes a language: Biodata teaching Dr Shai Melcer, head of bio-convergence at the Israel Innovation Authority, discusses biology as a language ahead of Biomed Israel 2026.
R&D On the ICH E20 draft guideline (2025) for adaptive clinical ... A review of the scope, key principles, methodological expectations, and regulatory implications of ICH E20.
R&D Sandoz on the future of generics and biosimilars in Europe At Reuters Pharma Europe, Sandoz' Claire D'Abreu-Hayling explored the promise of the so-called “golden decade” of patent expiry for generics.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
